NuVasive

  • Revenue$1.1 BFY, 2021
  • Market Capitalization$2.6 B2022-06-29

OverviewSuggest Edit

NuVasive is a medical device company that develops, manufactures, sells, and provides integrated solutions for spine surgery. It offers solutions for a range of conditions such as degenerative disc disease, lumbar spinal stenosis, degenerative spondylolisthesis, cervical disc degeneration, etc. The company offers product types such as surface and structural technologies, orthopedic solutions, and various medical platforms.
TypePublic
Founded1997
HQSan Diego, CA, USMap
Websitenuvasive.com
Employee Ratings3.9
Overall CultureB-More
View Jobs (212)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2021)2,900(+8%)
Job Openings212
Revenue (FY, 2021)$1.1 B(+9%)
Share Price (Jun 2022)$50
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at NuVasive

Chris Barry

Chris Barry

Chief Executive Officer
Matt Harbaugh

Matt Harbaugh

Executive Vice President and Chief Financial Officer
Dale Wolf

Dale Wolf

Senior Vice President, Global Operations
Nathaniel Sisitsky

Nathaniel Sisitsky

Senior Vice President, General Counsel and Corporate Secretary
Aviva McPherron

Aviva McPherron

Senior Vice President, Information Technology
Michael Farrington

Michael Farrington

Vice President, Corporate Marketing, Brand and Communication
Show more

NuVasive Office Locations

NuVasive has offices in San Diego, Aliso Viejo, Ann Arbor, Broomfield and in 11 other locations
San Diego, CA, US (HQ)
7475 Lusk Blvd
Aliso Viejo, CA, US
101 Enterprise
Ann Arbor, MI, US
3891 Ranchero Dr
Broomfield, CO, US
12101 Airport Way
Columbia, MD, US
10275 Little Patuxent Pkwy #300
Dayton, OH, US
805 Liberty Ln
Show all (16)

NuVasive Financials and Metrics

NuVasive Revenue

Embed Graph
View revenue for all periods
NuVasive's revenue was reported to be $1.14 b in FY, 2021
USD

Revenue (FY, 2021)

1.1b

Gross profit (FY, 2021)

816.7m

Gross profit margin (FY, 2021), %

71.7%

Net income (FY, 2021)

(64.1m)

Market capitalization (29-Jun-2022)

2.6b

Closing stock price (29-Jun-2022)

50.0

Cash (31-Dec-2021)

246.1m
NuVasive's current market capitalization is $2.6 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

1.2b1.1b1.1b

Cost of goods sold

312.4m321.6m322.3m

Gross profit

855.7m729.0m816.7m

Gross profit Margin, %

73%69%72%
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

274.8m292.1m290.8m259.9m203.6m295.3m271.2m294.8m270.8m

Cost of goods sold

74.5m77.6m77.0m71.9m80.5m84.6m71.8m78.3m88.7m

Gross profit

200.3m214.5m213.8m188.0m123.1m210.6m199.4m216.5m182.2m

Gross profit Margin, %

73%73%74%72%60%71%73%67%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

92.6m163.5m123.3m102.8m142.4m192.3m153.6m72.8m117.8m213.0m856.9m246.1m

Accounts Receivable

76.6m88.4m89.0m104.8m119.0m127.6m199.0m196.5m211.5m207.1m214.4m

Prepaid Expenses

19.9m8.5m10.9m21.6m8.8m18.8m13.7m16.9m19.7m20.7m

Inventories

107.6m119.3m126.3m136.9m154.6m168.1m208.2m247.2m273.2m312.4m300.6m315.8m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

67.5m70.6m134.1m505.1m220.9m270.2m121.2m107.7m78.5m58.9m100.6m110.8m106.5m130.7m88.5m78.6m141.3m270.1m263.1m203.8m134.0m130.9m62.2m73.7m70.1m75.1m93.4m128.4m163.4m512.0m796.8m774.5m233.9m204.1m

Accounts Receivable

68.2m71.6m76.0m80.5m78.6m85.6m85.7m78.1m90.4m96.3m96.2m106.3m112.6m108.4m111.5m116.8m115.6m126.1m141.9m143.8m172.1m190.2m187.2m188.1m199.9m191.6m194.4m208.0m203.6m186.8m182.1m205.3m205.0m216.9m

Prepaid Expenses

4.7m5.1m9.2m8.1m7.3m9.1m9.0m10.1m11.3m11.8m10.2m9.0m8.4m7.3m7.8m8.1m9.6m12.9m12.3m9.2m21.1m23.6m23.4m13.6m14.6m14.6m17.3m17.7m15.6m21.9m21.0m

Inventories

93.1m98.8m114.4m118.0m122.6m122.0m128.6m133.0m129.6m137.4m140.7m147.7m157.4m159.7m163.4m163.7m164.9m200.7m201.9m212.8m223.1m236.8m249.0m258.0m259.8m271.3m288.5m297.1m308.9m324.7m312.2m305.6m315.7m319.7m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

78.3m(69.8m)3.1m7.0m(17.5m)65.3m35.4m81.3m12.5m65.2m(37.2m)(64.1m)

Depreciation and Amortization

36.7m36.2m51.9m63.1m82.3m83.8m125.4m141.7m149.9m135.6m140.9m149.5m

Inventories

(18.7m)(17.2m)(11.0m)(21.0m)(21.3m)(26.0m)(22.6m)(35.3m)(38.6m)(54.9m)(40.8m)(37.0m)

Accounts Payable

11.6m(3.4m)2.9m21.8m22.3m7.7m11.9m(5.6m)20.5m(3.3m)8.8m533.0k
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

7.8m16.4m2.4m7.7m(59.8m)673.0k3.5m5.9m851.0k(5.6m)1.9m(18.3m)(22.4m)(24.2m)31.4m41.4m54.2m(9.3m)26.0m29.5m12.3m24.6m57.7m(27.1m)(15.6m)322.0k9.4m24.3m35.4m5.3m(44.7m)(38.8m)(7.5m)(5.7m)(27.3m)

Depreciation and Amortization

17.1m27.4m7.8m15.9m24.8m12.1m25.3m38.2m14.6m30.3m46.3m15.4m31.0m46.5m20.4m41.4m62.3m26.3m57.3m90.7m34.9m69.6m104.6m37.0m74.1m111.4m39.3m78.1m101.2m35.0m70.1m106.1m36.4m74.0m111.8m

Inventories

(4.3m)(10.0m)(6.7m)(12.1m)(19.9m)(3.5m)(11.0m)14.2m(4.1m)(13.7m)(16.7m)(11.7m)(20.9m)(27.2m)(11.4m)(15.2m)(19.8m)9.4m12.0m(22.4m)(13.6m)(29.0m)(36.2m)(12.1m)(19.6m)(33.5m)(19.3m)(31.9m)(45.6m)(21.1m)(33.0m)(37.5m)(12.5m)(20.4m)(29.3m)

Accounts Payable

4.6m6.3m4.0m(2.3m)504.0k7.8m7.1m4.5m10.4m8.8m10.4m4.5m5.1m16.0m17.4m6.8m8.8m10.0m14.3m5.9m593.0k5.0m(5.9m)1.6m9.0m21.7m(2.5m)9.3m7.4m(5.3m)1.3m10.2m(5.7m)(5.2m)(779.0k)
show all
USDQ2, 2010

Financial Leverage

2.1 x
Show all financial metrics

NuVasive Acquisitions / Subsidiaries

Company NameDateDeal Size
Simplify MedicalFebruary 24, 2021$150 m
SafePassageDecember 12, 2017
Vertera SpineSeptember 07, 2017
Biotronic NeuroNetworkJune 06, 2016$98 m
Ellipse TechnologiesJanuary 05, 2016$410 m
NuVasive Clinical Services Monitoring, Inc.
NuVasive Japan KK
NuVasive Specialized Orthopedics, Inc.
NuVasive Technology International Limited

NuVasive Revenue Breakdown

Embed Graph

NuVasive revenue breakdown by business segment: 75.2% from Spinal Hardware and 24.8% from Surgical Support

NuVasive revenue breakdown by geographic segment: 77.0% from United States and 23.0% from International (excludes Puerto Rico)

Human Capital Metrics

Source: www.sec.gov, www.nuvasive.com
Embed Graph

NuVasive Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

Learn more about our premium products
SecurityScorecard logo

NuVasive Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

NuVasive Online and Social Media Presence

NuVasive's Trends

Embed Graph

NuVasive Company Culture

  • Overall Culture

    B-

    70/100

  • CEO Rating

    C+

    69/100

  • Compensation

    D

    56/100

Learn more on Comparably

NuVasive News and Updates

April 21, 2022

NuVasive Simplify Cervical Disc Two-level Data Published in Journal of Neurosurgery: Spine

Peer-reviewed results from the two-level multi-center FDA Investigational Device Exemption study reiterate disc's superiority to ACDF SAN DIEGO, April 21, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery...
April 15, 2022

Global Interspinous Spacers Market to 2029 - Featuring Medtronic, Zimmer Biomet and NuVasive Among Others

Dublin, April 15, 2022 (GLOBE NEWSWIRE) -- The "Interspinous Spacers Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
February 08, 2022

NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full Year 2021 Results

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full year...
January 05, 2022

NuVasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Company's Thoracolumbar Interbody Portfolio

SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company received U.S. Food and Drug Administration...
December 28, 2021

NuVasive to Participate in 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 28, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Executive Officer Chris Barry will virtually...
November 18, 2021

NuVasive to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive CEO J. Christopher Barry will virtually...
Show more

NuVasive Blogs

June 29, 2022

NuVasive Opens Singapore Experience Center for Asia-Pacific region

New center supports the Company's globalization efforts through increased surgeon training and education in Asia-Pacific region SAN DIEGO , June 29, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally
May 04, 2022

NuVasive Announces First Quarter 2022 Financial Results

–  Strong year-over-year net sales growth, driven by new product introductions and International sales – –  Company raises lower end of full-year 2022 financial guidance range – SAN DIEGO , May 4, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused
April 26, 2022

NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening

SAN DIEGO , April 26, 2022 /PRNewswire/ --  NuVasive, Inc. (NASDAQ: NUVA) today announced a milestone of more than 100 peer-reviewed publications of the Precice ®  System (Precice) for conditions related to limb lengthening and reconstruction from NuVasive Specialized Orthopedics™ (NSO).
April 20, 2022

NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results

NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results Content Import Wed, 04/20/2022 - 16:10 NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results April 20, 2022 General SAN DIEGO, April 20, 2022 /PRNe…
March 31, 2022

Celebrate Women Month Recap

  During March, NuVasive’s Employee Resource Group, Women In NuVasive (WIN) honored and celebrated Women’s History Month and International Women’s Day through their Celebrate Women series focused on the international theme for 2022, #BreakTheBias. WIN is a woman-led organization that is focused on b…
March 03, 2022

Black History Month 2022 highlights

During February, NuVasive recognized and celebrated Black History Month for the second year. The month was an incredible time to celebrate the contributions and legacy of African Americans across U.S. history and the world. During the month, employees had the opportunity to engage in events with the…
Show more

 NuVasive Frequently Asked Questions

  • When was NuVasive founded?

    NuVasive was founded in 1997.

  • Who are NuVasive key executives?

    NuVasive's key executives are Chris Barry, Matt Harbaugh and Dale Wolf.

  • How many employees does NuVasive have?

    NuVasive has 2,900 employees.

  • What is NuVasive revenue?

    Latest NuVasive annual revenue is $1.1 b.

  • What is NuVasive revenue per employee?

    Latest NuVasive revenue per employee is $392.8 k.

  • Who are NuVasive competitors?

    Competitors of NuVasive include DePuy Synthes, Stryker and Integra LifeSciences.

  • Where is NuVasive headquarters?

    NuVasive headquarters is located at 7475 Lusk Blvd, San Diego.

  • Where are NuVasive offices?

    NuVasive has offices in San Diego, Aliso Viejo, Ann Arbor, Broomfield and in 11 other locations.

  • How many offices does NuVasive have?

    NuVasive has 16 offices.